Anty Rodolphe, Gual Philippe, Huet Pierre-Michel, Marchand-Brustel Yannick Le, Tran Albert
Inserm, U568, Nice.
Gastroenterol Clin Biol. 2007 Dec;31(12):1127-34. doi: 10.1016/s0399-8320(07)78350-1.
Metabolic fatty liver diseases (Non Alcoholic Fatty Liver Diseases-NAFLD) are liver abnormalities (steatosis and steatohépatitis) commonly related to visceral obesity and to the metabolic syndrome. The pathogenesis of metabolic fatty liver diseases is most probably linked to the adipose tissue insulin resistance with a very high free fatty acids release, an abnormal secretion of factors produced by the adipose tissue (adipokines) and a low grade of chronic inflammation. The link between metabolic fatty liver diseases and the metabolic syndrome is further supported by epidemiological studies, as well as the frequently encountered cardio-vascular complications in both diseases. Changes in lifestyle with dietary restriction and increased physical activity are mandatory and similar for both conditions. Drugs such as thiazolidinediones, known to reduce insulin resistance and inflammation, still need further evaluation.
代谢性脂肪性肝病(非酒精性脂肪性肝病-NAFLD)是常见的与内脏肥胖和代谢综合征相关的肝脏异常(脂肪变性和脂肪性肝炎)。代谢性脂肪性肝病的发病机制很可能与脂肪组织胰岛素抵抗有关,伴有极高的游离脂肪酸释放、脂肪组织产生的因子(脂肪因子)分泌异常以及低度慢性炎症。代谢性脂肪性肝病与代谢综合征之间的联系得到了流行病学研究的进一步支持,以及这两种疾病中经常出现的心血管并发症。通过饮食限制和增加体育活动来改变生活方式对于这两种情况都是必要且相似的。噻唑烷二酮类药物等已知可降低胰岛素抵抗和炎症的药物仍需进一步评估。